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Bangkok, ThailandA B S T R A C TObjective: To compare the cost utility of using erythropoietin (EPO) to
maintain different hemoglobin (Hb) target levels in hemodialysis
patients from a societal perspective. Methods: A Markov model was
used to estimate the incremental cost and quality-adjusted life-year
of ﬁve Hb levels: 9 or less, more than 9 to 10, more than 10 to 11, more
than 11 to 12, and more than 12 g/dl. A systematic review of EPO
treatment in hemodialysis patients was conducted to estimate transi-
tional probabilities. Cost data were estimated on the basis of the
reference price of Siriraj Hospital, the largest university hospital in
Thailand. Utility scores were derived from the six-dimensional health
state short form (derived from short-form 36 health survey), which
were collected from 152 hemodialysis patients receiving EPO at Siriraj
hospital. Probabilistic sensitivity analysis was conducted to investi-
gate the effect of uncertain parameters. All future costs and outcomes
were discounted at the rate of 3% per annum. Results: The incre-
mental cost-effectiveness ratios of Hb levels more than 9 to 10, moresee front matter Copyright & 2014, International S
r Inc.
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angkok, Thailand 10700.than 10 to 11, more than 11 to 12, and more than 12 g/dl compared
with the least costly option (Hb r 9 g/dl) were US $24,128.03, US
$18,789.07, US $22,427.36, and US $28,022.33 per quality-adjusted life-
year, respectively. From probabilistic sensitivity analysis, the hemo-
globin level of more than 10 to 11 g/dl was appropriate when the
willingness to pay was US $15,523.88 to US $46,610.17 and the
probability of cost-effective was 29.32% to 95.94%. Conclusions: Pro-
viding EPO for a hemoglobin level of more than 10 to 11 g/dl had a
cost-effectiveness higher than that of doing so for other hemoglobin
levels. This ﬁnding will be put forward to the policy level to set up the
EPO treatment guideline of the hospital for hemodialysis patients.
Keywords: cost-utility analysis, end-stage renal disease, erythro-
poietin, hemodialysis, Markov model.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Twenty-ﬁve years have passed since the ﬁrst patient received
recombinant human erythropoietin (EPO) in Seattle in November
1985 [1,2]. EPO is effective in reversing anemia of renal failure and
all its diverse consequences. A reduction in hemoglobin (Hb)
levels in these patients has been shown to be associated with
impairment in quality of life (QOL), reduced energy, neurocogni-
tive decline, decreased exercise capacity, and increased mortality
[3–6]. The cause of anemia in the patients is mainly related to a
deﬁciency in the synthesis of endogenous EPO [7]. Therefore, the
use of recombinant human EPO represents a logical and com-
monly used treatment for this disorder. EPO has been shown to
improve QOL, exercise capacity, cognitive function, and sleep
disturbances and ameliorate left ventricular hypertrophy, which
is a major contributor to cardiac mortality and morbidity in
patients with end-stage renal disease (ESRD) [8–13]. Most patients
receiving hemodialysis (HD) for ESRD currently receive EPO foranemia treatment. Anemia from EPO deﬁciency is a common
complication of chronic kidney disease (CKD). It can be treated
with EPO administration, red blood cell transfusion, or a combi-
nation of both [14]. But the widely accepted use in patients with
anemia is EPO administration. Early studies found that EPO
reduced the need for transfusions and improved the QOL in
patients with CKD, when compared with not using EPO [15,16].
EPO is routinely used to treat anemia of CKD, especially in
patients who need dialysis. The goal of therapy is to achieve
speciﬁc Hb target levels. Higher doses of EPO, however, are being
used to attain higher target levels without evidence of corre-
sponding clinical beneﬁt and possibly resulting in harm. It is
remarkable that the three largest studies and a meta-analysis,
involving 3268 subjects, have had a very consistent outcome, a
21% to 48% increased risk for mortality in the higher Hb target
group, which in each study nearly reached statistical signiﬁcance
[11,17–19]. The Food and Drug Administration in the United
States suggests that increasing the hemoglobin level to moreociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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mortality and that the beneﬁts of these drugs have not been well
documented and this would imply that the Food and Drug Admin-
istration asserts an Hb target level of only 10 g/dl because this level
is far from the range of demonstrated risk [20] while the cost
consequences of using EPO to achieve higher Hb targets is increas-
ing. In 2007, the Food and Drug Administration ruled that mini-
mization of blood transfusions and low red blood cell levels were
the predominant indications for EPO in anemic patients with CKD;
regarding low red blood cell levels, the recommendation of Hb levels
is 10 to 12 g/dl [21]. Nowadays, target Hb levels in CKD remain
uncertain because Hb target levels above 13 g/dl have been
associated with both beneﬁt (QOL) and harm (cardiovascular events)
[22]. Many HD patients receive EPO for their anemia as a part of
routine therapy. Because EPO is an expensive therapy, it has created
an economic burden onto the health care system of every country
including a developing country such as Thailand. The purpose of
this study was to evaluate the cost-effectiveness of EPO use for
different target Hb levels at the resources of a developing country.Methods
A Markov model was constructed to estimate the incremental
costs and QALY gains associated with EPO treatment for main-
taining Hb levels of more than 9 to 10, more than 10 to 11, more
than 11 to 12, and more than 12 g/dl compared with 9 g/dl or less.
The study adopted a societal perspective. The results were
presented in terms of incremental costs (US $), incremental
quality-adjusted life-years (QALYs) gained, and incremental
cost-effectiveness ratio (ICER). The HD patients may be alive with
a cardiovascular (CV) event or a noncardiovascular (nCV) event
such as catheter-related infections and then they have a chance
of dying from a CV event (death from the CV state) or an nCV
event (death from the nCV state). So, the Markov model was
viewed as four states: dead from CV, dead from nCV, alive with
HD, and alive with hemodialysis and cardiovascular disease
(HDCV), as shown in Figure 1. The four health states were deﬁned
by the solid line ovals and occurred in each Hb level (ﬁve Hb
levels such asr9,49–10,410–11,411–12, and412 g/dl). A ﬁxed
1-year cycle length was assigned. The time horizon of the
analysis was the lifetime of the patient.
In this Markov model, we classiﬁed HD patients into two groups:
1) the patients who were alive with HD (the HD state) and 2) the
patients who were alive with HDCV treatment (the HDCV state).
When the HD state’s patients moved to the HDCV state (arrow no.
1), they could not move back to the HD state because they would beFig. 1 – Schematic representation of Markov model. CV,
cardiovascular; nCV, noncardiovascular; HD, hemodialysis;
HDCV, hemodialysis and cardiovascular disease.treated CV forever. The HD state’s patients, however, stayed in the
HD state if no event occurred (dotted-line arrow no. 2) or if they
successfully completed the nCV treatment (arrow no. 3). When the
nCV treatment was not successful, they moved to the state of death
from the nCV event (arrow no. 4). The HDCV patients stayed in the
HDCV state when no event occurred (dotted-line arrow no. 5) or
they successfully completed the nCV treatment (arrow no. 6). When
the nCV or CV treatment was not successful, they moved to the
state of death from the nCV event (arrow no. 7) or the CV event
(arrow no. 8). It was assumed that once the patients have HD or
HDCV, they would continue to hemodialyse until dead (absorbing
health state). Costs and QALYs gained were calculated as patients
went through the model. The moving of any state was assumed to
be independent of their moving Hb level. The movement between
each state was determined by probabilities that were obtained from
randomized controlled trials (RCTs) and systematic reviews.Transitional Probability Data
Transitional probabilities used in this study were obtained
mainly from systematic review of the literature using the PubMed
database, the National Coordinating Centre for Health Technol-
ogy Assessment, the Cochrane library, and the ClinicalTrials.gov
Web site. Search dates were between January 1, 1966, and
December 31, 2009. All searches included the keywords and
corresponding MeSH terms for erythropoietin, kidney disease,
renal disease, hemodialysis, randomized controlled trial (RCTs),
meta-analysis, and practice guideline. These studies included the
studies of efﬁcacy of EPO (e.g., erythropoietin beta, and alfa); the
methodology of the studies was RCTs, meta-analysis of RCTs,
which assessed the effects of targeting different Hb concentra-
tions when treating patients with anemia caused by CKD with
EPO, and the targeted patients were older than 18 years. These
studies excluded nonrandomized trials or RCTs that were evalu-
ating other interventions such as subcutaneous versus intra-
venous EPO treatment for anemia of CKD; outcomes such as
blood viscosity and hematopoietic progenitor cell assays were
reported.
We identiﬁed 277 potentially eligible articles, 204 of which were
excluded because these were not RCTs. Seventy-three RCTs con-
sisted of 22 studies that assessed the dose and route of admin-
istration, 15 hematological and hemodynamic effects studies, and
21 other intervention studies, that is, nutritional supplement.
Thirteen RCTs and 2 meta-analyses of RCTs of EPO in CKD were
full articles but only 4 RCTs [11,12,23,24] met the speciﬁed inclusion
criteria. These studies were conducted in Canada and Europe. There
was no study conducted in Thailand or Asia. From the clinical trial,
we derived the compound mortality rate and then we calculated
the disease-speciﬁc mortality rate using the following formula:
μC ¼ μDþμASR
where μD is the disease-speciﬁc excess mortality rate (ﬁxed rate), μC
is the compound mortality rate derived from the study in the
literature, and μASR is the age-, sex-, race-adjusted mortality rate.
μASR ¼ 1=LEASR
where LEASR (ASR is the age-, sex-, race-adjusted life expectancy) is
the life expectancy of the Thai general population classiﬁed by age
group (derived from Life Table of Vital Statistics Thailand 2006 [25]).
When we knew the mortality rate for different ages, we
converted the rate to probability (P), assuming that an event
occurs at a constant rate (r) over a time period between time zero
to sometime beyond, such as the time period between the ﬁrst
year and the ﬁfth year is 4 (t):
P ¼ 1–erate
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Utility in this study used the six-dimensional health state short
form (calculated from the short-form 36 survey) (SF-6D) and
derived from the previous study during November-December
2009 with 152 HD patients (22 HD patients with a history of a
CV event and 130 HD patients without a history of a CV event) at
Siriraj Hospital where the patients come from throughout Thai-
land [26]. From the short-form 36 survey score in the previous
study, the SF-6D utility was calculated by applying the scoring
method that was also derived from UK preference scores by using
the computer algorithm [27] because preference weights of the
SF-6D for Thai people were not available.
QALY Calculation
QALYs were calculated as the number of additional years of life
gained from an intervention multiplied by a utility judgment of
the QOL. The QALYs gained can be calculated using the proba-
bilities to determine the mean, variance, and probability distri-
bution for the QALYs gained. It was carried out using TreeAgePro
2009 (TreeAge Software, Inc., Williamstown, MA).
Cost Parameter
Direct medical costs were estimated on the basis of the reference
price of the hospital. The treatment costs incurred at the
inpatient department were estimated on the basis of the actual
treatment costs of HD, CV event including myocardial infarction,
stroke, heart failure, or revascularization (percutaneous trans-
luminal coronary angioplasty or coronary-artery bypass grafting)
resulting in hospitalization for 24 hours or more or prolongation
of hospitalization, and nCV events including other events except
the CV event resulting in hospitalization for 24 hours or more or
prolongation of hospitalization. The events were classiﬁed byTable 1 – Mean and standard error (SE) of transitional pr
Parameter
P(t) among HD (no CV) patients received EPO
P(t) of adverse event
P(t) of CV event
P(t) of nCV event
P(t) of CV event and dying (all Hb levels)
P(t) of CV event and still alive (all Hb levels)
P(t) of no adverse event (all Hb levels)
P(t) of dying from nCV event (all Hb levels, except Hb 4 12 g/dl)
P(t) of alive after having nCV event (all Hb levels, except Hb 4 12 g/dl
P(t) of dying from CV event (only Hb 4 12 g/dl)
P(t) of alive after having CV event (only Hb 4 12 g/dl)
P(t) among HDCV patients received EPO
P(t) of adverse event
P(t) of no adverse event
P(t) of CV event
P(t) of dying from CV event (all Hb levels, except Hb 4 12 g/dl)
P(t) of alive after having CV event (all Hb levels, except Hb 4 12 g/dl)
P(t) of nCV event (all Hb levels, except Hb 4 12 g/dl)
P(t) of dying from nCV event (all Hb levels, except Hb 4 12 g/dl)
P(t) of alive after having nCV event (all Hb levels, except Hb 4 12 g/dl
P(t) of dying from CV event (only Hb 4 12 g/dl)
P(t) of alive after having CV event (only Hb 4 12 g/dl)
P(t) of dying from nCV event (only Hb 4 12 g/dl)
P(t) of alive after having nCV event (all Hb levels, except Hb 4 12 g/dl
CV, cardiovascular; EPO, erythropoietin; Hb, hemoglobin; HD, hemo
noncardiovascular.using the International Statistical Classiﬁcation of Diseases, Tenth Revi-
sion, in 2009 and the event costs such as CV, nCV events that
occurred in HD patients were calculated using the average cost
method. Direct nonmedical costs (e.g., food cost, traveling costs, and
accommodation costs for patients and their caregivers) were
derived from structured questionnaire interviews from 152 patients
receiving HD between November and December 2009. Indirect
nonmedical cost such as income lost as a result of sick leave or
hospital visits was calculated by multiplying the minimum wage in
2010 (US $6.35 per day) with the length of stay from the sick leave or
providing informal care (days). Mortality costs were excluded to
avoid double counting because health outcomes such as QALYs had
already taken into account the effects of mortality [28].
Annual EPO costs were derived from the unit cost of EPO
multiplied by the amount of use per year. The unit cost of EPO
was calculated from the average unit cost of EPO, that is, the
reference price of multiple brands at the largest university
hospital in Thailand in 2010 (unit cost ¼ US $0.010). For this
model, EPO was given when the Hb level start at 8 g/dl. The EPO
dose was calculated by using the following formula:
D ¼ 2400 IU=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
9:6= HbSS–Hb0ð Þ
 1
q
The dose per time (D) was expected to increase the Hb level from
a pretreatment level (Hb0) to a desired steady state level (HbSS)
when given intravenously three times per week [29].
Sensitivity Analysis
Probabilistic sensitivity analysis was performed by using Monte-
Carlo simulation. Monte-Carlo simulation was used by involving
random sampling of each variable under the speciﬁed probability
distribution within the model to produce more than 1000 iter-
ations. All input parameters were assigned probabilityobability parameters.
Parameter
distribution
Mean SE Source
Beta 0.798 0.004 [12]
Beta 0.110 0.026 [12]
Beta 0.890 0.006 [12]
Beta 0.030 0.029 [12]
Beta 0.970 0.002 [12]
Beta 0.202 0.070 [12]
Beta 0.027 0.025 [11–13]
) Beta 0.973 0.001 [12]
Beta 0.135 0.024 [12]
Beta 0.865 0.024 [12]
Beta 0.397 0.009 [6]
Beta 0.603 0.022 [6]
Beta 0.132 0.021 [6]
Beta 0.080 0.023 [6]
Beta 0.920 0.005 [6]
Beta 0.868 0.009 [6]
Beta 0.033 0.025 [6]
) Beta 0.967 0.002 [6]
Beta 0.090 0.023 [6]
Beta 0.910 0.005 [6]
Beta 0.049 0.024 [6]
) Beta 0.951 0.002 [6]
dialysis; HDCV, hemodialysis and cardiovascular disease; nCV,
Table 2 – Mean and standard error (SE) of utility
parameter.
Target
hemoglobin
Parameter
distribution
Mean SE
HDCV patient with hemoglobin level (g/dl)
r9 Beta 0.633 0.030
49–10 Beta 0.667 0.029
410–11 Beta 0.709 0.018
411–12 Beta 0.724 0.022
412 Beta 0.754 0.020
HD (no CV) patient with hemoglobin level (g/dl)
r9 Beta 0.680 0.032
49–10 Beta 0.716 0.031
410–11 Beta 0.761 0.020
411–12 Beta 0.777 0.024
412 Beta 0.809 0.022
CV, cardiovascular event; HDCV, hemodialysis and cardiovascular
disease.
Table 3 – Mean and standard error (SE) of annual
cost parameters.
Parameter Parameter
distribution
Mean SE
Cost of EPO (US $) to maintain Hb level (g/dl)
8–9 (1,711.75 units
per week)
Gamma 890.11 92.66
9–10 (3,157.17 units
per week)
Gamma 1,641.73 60.99
10–11 (4,337.64 units
per week)
Gamma 2,255.57 57.80
11–12 (5,529.26 units
per week)
Gamma 2,875.22 61.61
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range of values that each input parameter could attain. All cost
parameters were assigned to use gamma distribution and the
probability and utility parameters, which were bounded zero-one,
used beta distribution.
Discounting
All future costs and future outcomes were discounted at the rate
of 3% per annum.412 (7,659.19 units
per week)
Gamma 3,982.78 110.99
Cost of HD (US $) Gamma 8,286.43 128.48
Cost for HD patient (US $)
CV treatment but
ﬁnally dead
Gamma 8,116.25 1,547.09
CV treatment and
alive
Gamma 5,348.94 464.03
nCV treatment but
ﬁnally dead
Gamma 9,711.18 1,152.35
nCV treatment and
alive
Gamma 2,606.05 170.98
Cost for HDCV patient (US $)
CV treatment but
ﬁnally dead
Gamma 10,129.31 2,296.16
CV treatment and
alive
Gamma 5,657.02 832.19
nCV treatment but
ﬁnally dead
Gamma 6,787.27 1,891.40
nCV treatment and
alive
Gamma 5,016.22 526.45
Cost of direct nonmedical cost for treatment (US $)
CV event (per time) Gamma 443.41 93.17
nCV event (per time) Gamma 421.85 88.64
Length of stay when admits for treating (d)
nCV event Gamma 15.65 0.877
CV event Gamma 16.45 1.53
Income loss from CV
event leave (US $)
Gamma 107.92 107.92
Income loss from nCV
event leave (US $)
Gamma 101.57 101.57
CV, cardiovascular event; EPO, erythropoietin; Hb, hemoglobin;
HD, hemodialysis; HDCV, hemodialysis and cardiovascular dis-
ease; nCV, noncardiovascular event.Results
Transitional Probability Data
Transitional probability parameters are shown in Table 1.
Utility Data
We found that the average utility score of HD patients treated to
Hb levels of less than 9, more than 9 to 10, more than 10 to 11,
more than 11 to 12, and more than 12 g/dl was 0.672  0.161, 0.709
 0.132, 0.753  0.124, 0.769  0.139, and 0.801  0.122, respec-
tively. The utility scores of SF-6D were signiﬁcantly different
across Hb levels (P ¼ 0.005). This model assumed that the utility
scores of HDCV patients were lower by 5.9% when compared with
all HD patients and lower by 6.9% when compared with HD (no
CV) patients [26]. Thus, the utility scores of ﬁve group levels were
examined for cost-utility analysis, as shown in Table 2.
Cost Data
The cost parameters in the model are shown in Table 3. For
intercountry comparisons, cost parameters were converted to US
$ using the purchasing power parity exchange rate of US $1 ¼
32.45 (April 2010) Thai baht.
Cost-Effectiveness Analysis
Total cost of the least costly option (Hb r 9 g/dl) was US
$136,113.25 for 7.39 QALYs. The incremental costs of patients
with an Hb level of 9 g/dl or less compared with more than 9 to 10
g/dl, more than 10 to 11 g/dl, more than 11 to 12 g/dl, and more
than 12 g/dl were US $8,686.09, US $15,978.36, US $23,324.45, and
US $30,264.12, respectively, while the incremental QALYs gained
were 0.36, 0.85, 1.04, and 1.08, respectively. The ICER of Hb levelsmore than 9 to 10, more than 10 to 11, more than 11 to 12, and
more than 12 g/dl compared with the least costly option (Hbr 9 g/
dl) was US $24,128.03, US $18,789.07, US $22,427.36, and US
$28,022.33 per QALY, respectively. The minimum ICER was the
ICER of Hb level more than 10 to 11 g/dl. Hb level of more than 10
to 11 g/dl appeared more cost-effective than other Hb levels. When
the ICER was calculated from all incremental costs and QALYs, it
was conﬁrmed that Hb level of more than 10 to 11 g/dl was still the
cost-effective option, as shown in Table 4. (The ICER of patients at
Hb level of more than 10 to 11 g/dl when compared with Hb level
of more than 9 to 10 g/dl was US $14,882.19 per QALY.)
Probabilistic Sensitivity Analysis
The results of the probabilistic sensitivity analysis were pre-
sented in terms of cost-effectiveness acceptability curves, as
Table 4 – Cost-effectiveness results obtained from
the analysis.
Comparator
strategies
Incremental
cost (US $)
Incremental
QALY (QALY)
ICER (US
$/QALY)
All incremental relative to the lowest cost option (Hb r 9 g/dl)
49–10 g/dl vs.
r9 g/dl
8,686.09 0.36 24,128.03
410–11 g/dl vs.
r9 g/dl
15,978.36 0.85 18,789.07
411–12 g/dl vs.
r9 g/dl
23,324.45 1.04 22,427.36
412 g/dl vs. r9
g/dl
30,264.12 1.08 28,022.33
All incremental relative to the next Hb level
49–10 g/dl vs.
r9 g/dl
8,686.09 0.36 24,128.03
410–11 g/dl
vs. 49–10 g/dl
7,292.27 0.49 14,882.19
411–12 g/dl vs.
410–11 g/dl
7,346.08 0.19 38,663.60
412 g/dl vs.
411–-12 g/dl
6,939.67 0.04 173,491.76
Hb, hemoglobin; ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life-year.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 4 4 – 4 948shown in Figure 2. Providing EPO for patients with an Hb level of
more than 9 to 10 g/dl was appropriate when the willingness to
pay (WTP) was less than US $15,523.88, while the Hb level of more
than 10 to 11 g/dl was the optimal choice if the WTP was between
US $15,523.88 and US $46,610.17 and the probability of being cost-
effective was between 29.32% and 95.94%.Discussion
Higher Hb levels yielded higher QALYs and higher cost of EPO;
thus, the optimal strategy should be considered from the lowestFig. 2 – Cost-effectiveness acceptability curve of the different HbICER. When the initial Hb level of an HD patient was less than
9 g/dl, providing EPO for the Hb level of more than 10 to 11 g/dl was
less costly at a higher effectiveness than doing so for other Hb
levels. Practicing an EPO treatment target Hb level of more than 10
to 11 g/dl yielded an incremental cost per QALY of about US
$18,789.07. In 2009, Thai gross domestic product (GDP) per capita
was US $4,162.50 [30]. The World Health Organization recom-
mended the ICER per QALY gained of medical interventions below
one time of GDP per capita as maximum cost-effective, between 1
and 3 times of GDP per capita as cost-effective, and more than 3
times of GDP per capita as not cost-effective [31]. These implied a
ceiling threshold of US $12,327 per QALY in Thailand. As per the
above results and based on the recommendations, all strategies
were considered cost-ineffective. The results of this study clearly
indicated that the lowest ICER was for the Hb level of more than 10
to 11 g/dl while the highest ICER was for the Hb level of more than
12 g/dl on comparing each Hb level with Hb levels of 9 g/dl or less.
These ﬁndings supported the need to allocate the available
resources to cover more people with an Hb level of more than 10
to 11 g/dl for anemia treatment and improve their QOL. The results
of this evaluation indicated that providing EPO for an Hb level of
more than 12 g/dl was associated with unfavorable cost-effective-
ness ratios based on the societal perspective of a developing
country such as Thailand. In sensitivity analysis, the level of more
than 9 to 10 g/dl was appropriate when the WTP was less than US
$15,523.88 while the Hb level of more than 10 to 11 g/dl was the
optimal choice if the WTP was between US $15,523.88 and US
$46,610.17 and the probability of being cost-effective was between
29.32% and 95.94%.
The ﬁndings of this study have shown that if policymakers
were willing to pay at US $12,327 (3 times of GDP per capita in
Thailand) per QALY gained, providing EPO for anemia treatment
for all Hb levels may be deemed a cost-ineffective strategy for all
HD patients but practicing an EPO treatment target Hb level of
more than 10 to 11 g/dl yielded minimum incremental cost per
QALY. Although the Hb level of 11 to 12 g/dl was the recommen-
dation for anemia treatment in many guidelines, providing EPO
for patients with an Hb level of more than 11 to 12 g/dl was
considered less cost-effective than providing EPO for patients
with an Hb level of more than 10 to 11 g/dl in a developinglevels compared with the Hb levelso9 g/dl. Hb, hemoglobin.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 4 4 – 4 9 49country such as Thailand. The Hb level of more than 12 g/dl was
the least cost-effective option when compared with other Hb
levels.
Limitations of the Study
This study had no information on some epidemiological param-
eters such as the mortality rate of a CV event in HDCV or HD
patients that related to the Hb level studies in Thailand. For this
study, it was derived from RCTs or systematic review. There were
only four RCTs related to these events among HD patients of
other countries, which might be different from the Thai race. The
sensitivity analysis, however, was performed to ensure the
quality of the assessment and to produce a more realistic interval
on the study’s conclusions. The EPO dose of each Hb level was
deﬁned from the formula [29] that was the nearest practice for
the approximation of the EPO dose in real practice. It was
assumed that people with different CV risks or other character-
istics would receive a ﬁxed dose for each Hb level target. Titration
to a higher or lower dose of EPO, however, might be found in
realistic clinical practice. Disease treatment costs per annum of a
CV event and an nCV event were calculated by the summation of
service quantities received multiplied by its average cost. Quan-
tities of service and the average cost received were derived from
realistic data in HD patients of Siriraj Hospital but whether these
can be generalized to other settings needs to be considered. The
SF-6D utility was calculated by applying the scoring method that
was derived from a UK preference score (Thai preference score
was not available), which might be different from that for the
Thai race, but the sensitivity analysis was performed to ensure
the quality of the assessment. The utility score, however, was
estimated; further study should be done in longitudinal data.Acknowledgment
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